Tackling Sleeping Sickness: Current and Promising Therapeutics and Treatment Strategies

Area of Science:

• Neglected tropical diseases
• Parasitology
• Drug discovery

Background:

• Human African trypanosomiasis (HAT) is caused by *Trypanosoma brucei*, a protozoan parasite targeted for 2030 eradication.
• The COVID-19 pandemic disrupted control programs, potentially delaying HAT elimination.
• Vaccine development for HAT is hindered by parasite antigenic variation and B cell depletion.

Purpose of the Study:

• To review recent advances in anti-trypanosomal drug discovery for Human African Trypanosomiasis.
• To discuss novel drug targets and challenges in HAT eradication.
• To highlight the significance of fexinidazole as a new oral treatment option.

Main Methods:

• Review of recent scientific literature on anti-trypanosomal drug discovery.
• Analysis of challenges in Human African Trypanosomiasis control and eradication.
• Discussion of novel drug targets and therapeutic strategies.

Main Results:

• Fexinidazole represents a significant chemotherapeutic advancement as the first oral drug for HAT.
• Existing chemotherapeutics for HAT have faced issues with toxicity, resistance, and administration.
• Timely diagnosis and patient compliance remain critical for effective HAT treatment.

Conclusions:

• Despite challenges, ongoing drug discovery efforts are crucial for combating Human African Trypanosomiasis.
• Novel drug targets and improved therapeutic strategies are essential for disease eradication.
• Fexinidazole offers a promising new oral treatment, but compliance and resistance require continued attention.